Ropinirole Tablets Recalled for Manufacturing Practice Deviations
Accord Healthcare recalls 181,848 bottles of Ropinirole 0.5 mg tablets distributed in the U.S., Canada, and Puerto Rico due to manufacturing practice deviations identified during an FDA inspection.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is related to manufacturing deviations without specific product defect or reported harm, consistent with a Moderate severity classification.
Plain-English summary
Accord Healthcare, Inc. is recalling 181,848 bottles of Ropinirole 0.5 mg tablets distributed in the United States, including Puerto Rico, and Canada. The recall affects multiple batches with expiration dates ranging from March 31, 2023 through May 31, 2024.
An FDA inspection identified Current Good Manufacturing Practice (CGMP) deviations in the manufacturing process, prompting this Class II recall. The specific affected batches and their expiration dates are listed on the FDA's recall notice.
Ropinirole is a prescription medication used to treat Parkinson's disease and restless leg syndrome. Patients who believe they have affected bottles should contact their healthcare provider or pharmacist for guidance about their medication.
More information about this recall, including the complete list of affected batch numbers, is available on the FDA's official drug recall website.
The recalled product
- Product
- ROPINIROLE (ROPINIROLE)
- Brand
- ROPINIROLE
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- Affected units
- 181,848
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: P2102133
- P2102135
- P2102136
- Exp. Date 3/31/2023
- P2104998
- P2104997
- P2104991
- P2104992
- P2104990
- P2104993
- P2105000
- P2104999
- P2105002
- P2105001
- Exp. Date 7/31/2023
- P2106812
- Exp. Date
- 9/30/2023
- P2200433
- P2200434
UPCs (1)
- 316729233019
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 67 recalled by Accord Healthcare, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 67 products in this recall →Related recalls
Same brand · ROPINIROLE
- HighRopinirole tablets recalled due to FDA manufacturing compliance deviations
FDA (Drugs) · 2023-03-08
- HighRopinirole tablets recalled due to manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- HighFDA Recalls Ropinirole 3mg Tablets due to CGMP Deviations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled Due to Manufacturing Quality Violations
FDA (Drugs) · 2023-03-08
- ModerateRopinirole Tablets Recalled by Accord Healthcare Following FDA Inspection
FDA (Drugs) · 2023-03-08
Same manufacturer · Accord Healthcare, Inc.
See all →- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19